1. Show article details.

    Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases

    Benzinga – 11:35 AM ET 08/05/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours: The FDA cleared Marker Therapeutics Inc's  Investigational New Drug application for MT-601 for relapsed/refractory non-Hodgkin lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment. MT-601 is a multi-tumor-associated antigen-specific T cell product targeting six antigens.

  2. Show article details.

    Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study

    Benzinga – 11:12 AM ET 08/05/2022

    Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study

  3. Show article details.

    BRIEF-Akebia Therapeutics Reports Second Quarter 2022 Financial Results And Recent Business Highlights

    Reuters – 5:56 PM ET 08/04/2022

    Akebia Therapeutics Inc (AKBA): * AKEBIA THERAPEUTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS. * Q2 REVENUE $126.8 MILLION. * QTRLY EARNINGS PER SHARE $0.15 Source text for Eikon: Further company coverage:

  4. Show article details.

    Akebia Therapeutics: Q2 Earnings Insights

    Benzinga – 5:44 PM ET 08/04/2022

    Akebia Therapeutics reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Akebia Therapeutics beat estimated earnings by 148.39%, reporting an EPS of $0.15 versus an estimate of $-0.31. Revenue was up $73.85 million from the same period last year.

  5. Show article details.

    BRIEF-Akebia Therapeutics Announces Initial Findings From Study Evaluating Vadadustat

    Reuters – 4:58 PM ET 08/04/2022

    Akebia Therapeutics Inc (AKBA): * AKEBIA THERAPEUTICS ANNOUNCES INITIAL FINDINGS FROM INVESTIGATOR-SPONSORED CLINICAL STUDY EVALUATING VADADUSTAT FOR THE PREVENTION AND TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME IN SUBJECTS WITH COVID-19 AND HYPOXEMIA Source text for Eikon: Further company coverage:

  6. Show article details.

    Akebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

    PR Newswire – 4:05 PM ET 08/04/2022

    Akebia to host conference call on August 4 at 4:30 p.m. ET CAMBRIDGE, Mass.

  7. Show article details.

    Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Subjects with COVID-19 and Hypoxemia (VSTAT)

    PR Newswire – 4:02 PM ET 08/04/2022

    CAMBRIDGE, Mass. The trial enrolled 449 adult subjects at five hospitals who were randomized 1:1 to vadadustat 900 mg or placebo once per day orally for up to 14 days while hospitalized.

  8. Show article details.

    Earnings Scheduled For August 4, 2022

    Benzinga – 7:23 AM ET 08/04/2022

      ** Toyota Motor is projected to report earnings for its first quarter. ** Myriad Genetics is expected to report quarterly earnings at $0.01 per share on revenue of $171.00 million. ** Karyopharm Therapeutics is expected to report quarterly loss at $0.63 per share on revenue of $35.59 million.

  9. Show article details.

    Earnings Scheduled For August 4, 2022

    Benzinga – 4:23 AM ET 08/04/2022

      ** Toyota Motor is projected to report earnings for its first quarter. ** Myriad Genetics is expected to report quarterly earnings at $0.01 per share on revenue of $171.00 million. ** Karyopharm Therapeutics is expected to report quarterly loss at $0.63 per share on revenue of $35.59 million.

  10. Show article details.

    Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    PR Newswire – 4:05 PM ET 08/02/2022

    CAMBRIDGE, Mass. The options have an exercise price of $0.39 per share, which is equal to the closing price of Akebia's common stock on the grant date. About Akebia Therapeutics (AKBA) Akebia Therapeutics (AKBA), Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia Therapeutics ContactMercedes Carrascomcarrasco@akebia.com .

  11. Show article details.

    Why Amazon Is Trading Higher By 12%: Here Are 23 Stocks Moving Premarket

    Benzinga – 6:50 AM ET 07/29/2022

    Don't forget to check out our premarket coverage here .

  12. Show article details.

    Akebia Therapeutics to Report Second Quarter Financial Results

    PR Newswire – 8:00 AM ET 07/26/2022

    Akebia to Host Conference Call to Provide Business Update. CAMBRIDGE, Mass. Akebia will host a conference call on Thursday, August 4 at 4:30 p.m. ET to discuss its financial results and provide a general business update. A replay of the conference call will be available two hours after the completion of the call through August 10, 2022.

  13. Show article details.

    Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    PR Newswire – 4:05 PM ET 07/05/2022

    CAMBRIDGE, Mass. The options have an exercise price of $0.35 per share, which is equal to the closing price of Akebia's common stock on the grant date. About Akebia Therapeutics (AKBA) Akebia Therapeutics (AKBA), Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia Therapeutics ContactMercedes Carrascomcarrasco@akebia.com .

  14. Show article details.

    Accolade Shares Jump Around 29%, Here's 75 Biggest Movers From Friday

    Benzinga – 4:35 AM ET 07/05/2022

  15. Show article details.

    U.S. Stocks Turn Lower; Dow Tumbles Over 100 Points

    Benzinga – 12:20 PM ET 07/01/2022

    U.S. stocks turned lower midway through trading, with the Dow Jones dropping more than 100 points on Friday. The Dow traded down 0.44% to 30,639.41 while the NASDAQ fell 0.59% to 10,936.46. The S&P also fell, dropping, 0.46% to 3,767.81. Also check this: RH, Walgreens And 3 Stocks To Watch Heading Into Thursday Leading and Lagging Sectors Utilities shares rose by 1.4% on Friday.

  16. Show article details.

    Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session

    Benzinga – 12:06 PM ET 07/01/2022

    Why Is Akebia Therapeutics Surging By 28%? 48 Stocks Moving In Friday's Mid-Day Session

  17. Show article details.

    Why U.S. Stocks Are Trading Higher, Manufacturing Report And More

    Benzinga – 10:05 AM ET 07/01/2022

    U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. The Dow traded up 0.38% to 30,893.82 while the NASDAQ rose 0.50% to 11,084.33. The S&P also rose, gaining, 0.46% to 3,802.86. Also check this: RH, Walgreens And 3 Stocks To Watch Heading Into Thursday Leading and Lagging Sectors   Consumer discretionary shares rose by 1.7% on Friday.

  18. Show article details.

    The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact

    Benzinga – 8:53 AM ET 07/01/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours: The FDA's independent experts voted to include a SARS-CoV-2 omicron component in COVID-19 vaccines that would be used for boosters in the U.S. beginning in fall 2022.

  19. Show article details.

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    Benzinga – 8:11 AM ET 07/01/2022

      This article was generated by Benzinga's automated content engine and reviewed by an editor.

  20. Show article details.

    Akebia Therapeutics And 20 Stocks Moving Premarket

    Benzinga – 6:56 AM ET 07/01/2022

    Don't forget to check out our premarket coverage here .

Page:

Today's and Upcoming Events

  • Nov
    02

    AKBA to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    04

    AKBA announced Q2 earnings.

Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.